Show simple item record

dc.contributor.authorYoungson, J H
dc.contributor.authorJones, J M
dc.contributor.authorChang, James
dc.contributor.authorHarris, M A
dc.contributor.authorBanerjee, Saumitra S
dc.date.accessioned2010-05-19T09:59:42Z
dc.date.available2010-05-19T09:59:42Z
dc.date.issued1995-09
dc.identifier.citationTreatment and survival of lymphoid malignancy in the north-west of England: a population-based study. 1995, 72 (3):757-65 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid7669590
dc.identifier.urihttp://hdl.handle.net/10541/99261
dc.description.abstractClassification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients.
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshEngland
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell
dc.subject.meshLeukemia, Lymphoid
dc.subject.meshLymphoma, Non-Hodgkin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.meshRegistries
dc.subject.meshSurvival Rate
dc.titleTreatment and survival of lymphoid malignancy in the north-west of England: a population-based study.en
dc.typeArticleen
dc.contributor.departmentMerseyside and Cheshire Cancer Registry, University of Liverpool, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractClassification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients.


This item appears in the following Collection(s)

Show simple item record